The significance of a positive DAT in thalassemia patients by Arinsburg, Suzanne A. et al.
IMMUNOHEMATOLOGY, Volume 26, Number 3, 2010 87
The significance of a positive DAT in 
thalassemia patients
The DAT is performed for the detection of antibody or complement 
on the surface of RBCs. Our institution previously performed DATs 
on all chronically transfused thalassemia patients before each 
transfusion episode to detect early alloimmunization. The medical 
records of all thalassemia patients treated at our institution from 
2004 to 2007 were reviewed to determine the significance of the 
high rate of positive DATs (52.5% of 80 patients). The majority 
of IgG-reactive DATs were associated with a nonreactive eluate 
(65.4% of 286 eluates performed). A positive DAT was significant-
ly associated with splenectomy (χ2 = 15.4; p < 0.001), elevated IgG 
levels (χ2 = 26.8; p < 0.001), HCV (χ2 = 20.7; p < 0.001), and warm 
autoantibody (χ2 = 5.87; p = 0.03). Multivariate analysis revealed 
that only HCV (OR, 5.0; p = 0.037) and elevated IgG levels (OR, 
9.0; p = 0.001) were independently associated with a positive DAT. 
Alloimmunized thalassemic patients were more likely to have a 
positive DAT than nonalloimmunized patients, but this associa-
tion was not significant (OR, 2.2; p = 0.11). A positive DAT did not 
correlate with decreased response to transfusion, RBC survival, 
hemolysis, or increased transfusion requirements. Only two cases 
of early alloimmunization were detected by DAT among 288 DAT-
positive samples studied during 4 years. This study demonstrated 
that the routine performance of DATs on pretransfusion specimens 
in thalassemic patients has limited clinical utility, and the elimina-
tion of this test will improve turnaround time and decrease costs. 
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TThe DAT detects antibody, most commonly IgG, or complement on the surface of the RBC. Charac-terization of RBC-bound IgG includes identifying 
eluate reactivity and specificities. Eluates prepared from 
the RBCs of patients with autoantibodies (e.g., warm au-
toimmune hemolytic anemias or autoantibodies induced 
by certain drugs) can be panagglutinins, reacting with all 
RBCs. Eluates prepared from the RBCs of patients with 
serologic or hemolytic transfusion reactions contain IgG 
alloantibody(ies) with specificity for an RBC antigen. Oc-
casionally, an IgG eluate is not reactive with reagent RBCs. 
This is thought to be caused by an IgG antibody that is spe-
cific for an antigen that is not part of the RBC membrane, 
an antibody concentration that is too weak to be detected, 
or an elution method that does not remove the antibody or 
alters the antibody. It has also been shown that a certain 
number of IgG molecules normally attach to the erythrocyte 
surface in a nonimmunologic fashion. The degree of attach-
ment has been observed to have a direct relationship with 
the concentration of plasma IgG, and at high levels can lead 
to a positive DAT. This nonimmunologic attachment phe-
nomenon does not tend to cause decreased in vivo survival.1 
Studies have also shown that high serum IgG levels are not 
always associated with a positive DAT; therefore, factors in 
addition to an elevated serum IgG level must contribute to 
a positive DAT and nonreactive eluate.2 A positive DAT has 
also been linked with RBC senescence.
 Abnormalities in the immune system of children with 
β-thalassemia major have been previously documented, 
including an expansion of circulating B cells and a mod-
est polyclonal gammopathy in both splenectomized and 
nonsplenectomized patients.3 Immunologic abnormalities 
in this patient population are thought to be caused by the 
combined effect of chronic overstimulation of the immune 
system attributable to allogeneic transfusions, iron over-
load, and splenectomy.4 However, high immunoglobulin 
levels have been found in younger, not yet transfused pa-
tients with little iron storage,5 indicating that the disease 
itself, and not just treatment-related sequelae, may play a 
part in the abnormal IgG levels.
 Until 2007, a DAT was routinely performed on pre-
transfusion samples from β-thalassemic patients in our 
institution with intent to detect early alloimmunization. 
During a previous quality assurance review, we found only 
two cases of early alloimmunization detected by this means. 
Two of 288 positive DATs in thalassemic patients during 4 
years reviewed had a new alloantibody in the eluate that was 
not present in the serum. However, we found that greater 
than half of our regularly transfused β-thalassemic patients 
had a positive DAT, a much higher rate than other hospital-
ized patients. Approximately 1 to 15 percent of hospital pa-
tients and 0.01 to 0.1 percent of blood donors have a positive 
DAT.6 The cause, clinical significance, and serologic charac-
teristics of the positive DAT by routine laboratory methods in 
thalassemic patients have not been described. We performed 
this retrospective review of positive DATs in our thalassemic 
patients to determine whether a positive DAT in this popula-
tion is significant for transfusion therapy and to determine 
whether DAT surveillance is of value in screening chroni-
cally transfused subjects for alloimmunization. We hypothe-
sized that the positive DAT is attributable to multiple factors, 
including elevated IgG levels, and in the majority of cases is 
unlikely to be associated with immunization otherwise unde-
tectable by routine transfusion testing. Other areas of inquiry 
included the clinical significance of a nonreactive eluate for 
future transfusions and the effect on RBC survival.
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Materials and Methods
Patient Data
 The medical records of 80 β-thalassemia patients 
chronically transfused between 2004 and 2007 were re-
viewed. These patients collectively had 5696 transfusions 
and 288 positive DATs during this period at Weill Cornell 
Medical Center. Clinical data reviewed included patient 
age, sex, splenectomy status, IgG level, hepatitis C status, 
and other clinical history. Antibody screening and identi-
fication results, DAT and eluate results (including polyspe-
cific or IgG/C3bC3d), the number of units transfused, and 
the interval between transfusions were also analyzed. All 
available laboratory evidence of hemolysis was reviewed, 
including hemoglobin, hematocrit, haptoglobin, lactate 
dehydrogenase, and bilirubin levels. Transfusion response 
was assessed using pretransfusion hemoglobin levels at the 
subsequent visit. Approval to conduct the study was ob-
tained from the Weill Cornell Medical College Institutional 
Review Board.
Immunohematology Testing
 ABO grouping, D typing, and alloantibody screening 
were performed by standard semiautomated gel technol-
ogy (Provue Version 3.14B, Provue/Tecan; Ortho Clinical 
Diagnostics, Rochester, NY). Alloantibody identification on 
serum and eluates was performed using standard gel meth-
ods (Ortho Clinical Diagnostics and Immucor cell panels; 
Immucor, Norcross, GA). DATs were performed using IgG 
heavy chain–specific, rabbit-derived antibody and murine 
monoclonal C3bC3d. Acid elution was performed using 
low-pH glycine buffer.
Immunochemistry Testing
 Serum IgG concentrations were quantified using neph-
elometric methods (Beckman Immage; Beckman Coulter, 
Inc., Brea, CA). The IgG reference range is 1.8 to 3.3 g/dL, 
and all values greater than 3.3 g/dL were considered elevated.
 Screening for hepatitis C status was performed using 
an enzyme immunoassay (Vitros ECi-Q Immunodiagnostic 
System; Ortho Clinical Diagnostics). Confirmatory testing 
was performed using an in vitro qualitative enzyme immu-
noblot assay (Chiron RIBA HCV Strip Immunoblot Assay; 
Novartis Vaccines and Diagnostics, Inc., Emeryville, CA). 
All reactive enzyme immunoassays were confirmed positive 
by immunoblot.
Statistical Analysis
 Categorical variables were assessed by cross tabulation 
and tested for significance with χ2 or Fisher’s exact test. A 
probability value of less than or equal to 0.05 was considered 
significant. Continuous variables were reported as means with 
standard deviations and were tested for significance with the t 
test. Variables with a two-tailed significance value of p ≤ 0.05 
were included in logistic regression models to explore multi-
variable significance. Statistical testing was performed using 
Stata version 10.1 (StataCorp, College Station, TX).
Results
Clinical Patient Characteristics
 A total of 80 β-thalassemia patients regularly transfused 
from 2004 to 2007 were identified. Fifty-nine patients were 
diagnosed with β-thalassemia major and 21 patients were 
diagnosed with β-thalassemia intermedia (1 of whom was 
diagnosed as sickle cell and β-thalassemia intermedia). The 
majority (53 of 80) of these patients were only treated at 
our institution for thalassemia for the entirety of the study 
period. Patient characteristics including diagnosis, age, sex, 
and race are listed in Table 1. Overall, 68.8 percent (55 of 
80) of the patients were splenectomized and 61.3 percent 
(49 of 80) had an elevated immunoglobulin level (Table 2). 
All 80 patients were tested for hepatitis C; 36 were posi-
tive (45.0%). The mean number of transfusions per patient 
treated exclusively at this institution during this interval 
was 80.0 (range, 3–202; Table 3).
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Laboratory Patient Characteristics
 In addition to type and screen, a DAT (and eluate as 
required) was performed before each transfusion according 
to our institution’s standard operating procedure. Forty-
two patients had a positive DAT on at least one occasion, 
and 38 patients had no history of a positive DAT during 
the study period. The majority, 96.2 percent, of the posi-
tive DATs were positive owing to IgG (277 of 288) only, 0.7 
percent to complement (2 of 288) only, and 3.1 percent to 
both IgG and complement (9 of 288). Of the 286 eluates 
performed, 65.4 percent (187 of 286) were associated with 
a nonreactive eluate, 29.7 percent (85 of 286) with a pan-
agglutinin, 2.1 percent (6 of 286) with nonspecific reactiv-
ity, and 2.8 percent (8 of 286) with an alloantibody. The 85 
DATs with a panagglutinin were from the same 6 patients 
with a warm autoantibody.
Alloimmunization and Autoimmunization Rates
 The overall rate of alloimmunization was 32.5 percent 
(26 of 80) in this patient population. More than one allo-
antibody was detected in 69.2 percent (18 of 26) of immu-
nized patients. Table 4 presents the specificities of clinically 
significant alloantibodies by blood group antigens. Only 2 
cases of early alloimmunization to E and Jka were detected 
by a positive DAT only (negative serum antibody screen). 
Warm autoantibodies were detected in 7.5 percent (6 of 80) 
of all patients. Only 5 percent (4 of 80) of all patients were 
found to have both an alloantibody and an autoantibody.
Clinical and Demographic Factors Associated With 
a Positive DAT
 The DAT-positive and DAT-negative groups were simi-
lar with respect to sex. The DAT-positive patients were sig-
nificantly older than the DAT-negative patients (32.9 ± 12.7 
versus 20.7 ± 12.1 years; t test = 4.39; p = 0). There was 
a significant association between race, Caucasian versus 
Asian, and positive DAT (OR, 4.4; 95% CI, 1.52–12.46; p 
= 0.006). However, this difference was determined to be 
attributable to HCV status and age by logistic regression 
modeling. Although thalassemia intermedia patients were 
more likely to have a positive DAT (OR, 2.2) this was not 
statistically significant (p = 0.13).
 A positive DAT was associated with splenectomy (p < 
0.001), elevated IgG levels (p < 0.001), HCV (p < 0.001), 
and warm autoantibody (p = 0.03) in univariate testing 
(Tables 2 and 3). When adjusted for the effect of age, race, 
immunoglobulin level, and splenectomy status in logistic 
regression stepwise modeling, HCV was significantly as-
sociated with a positive DAT (OR, 5.0; p = 0.037). When 
adjusted for the effect of age, race, HCV, and splenectomy 
status in logistic regression stepwise modeling, an elevated 
IgG level was also significantly associated with a positive 
DAT (OR, 9.0; p = 0.001).
 The transfusion response was similar in the DAT-
positive and DAT-negative groups as determined by review 
of pretransfusion values at each visit. There was no clinical 
or laboratory evidence of hemolysis in any of the patients 
with a positive DAT (data not shown). Similarly, the total 
number of transfusions received at our institution between 
the two groups was not significantly different, suggesting 
there was no increased transfusion requirement among 
DAT-positive patients as a result of either hemolysis or 
other clinical factors (Table 3).
Laboratory Factors Associated With a Positive DAT
 Seventeen of the 42 patients (40.5%) with a history of 
a positive DAT were alloimmunized, and 9 of the 38 patients 
(23.7%) with no history of a positive DAT were alloimmunized. 











D 0 1 1
E 8 5 13
e 1 0 1
C 1 2 3
c 1 2 3
K 10 3 13
Jka 1 2 3
Jkb 1 0 1
Fya 1 0 1
Fyb 1 0 1
M 1 0 1
Low incidence
Bga 3 0 3
Kpa 2 1 3
Cw 1 0 1
V 3 0 3
VS 1 0 1
Jsa 2 0 2
Cob 1 0 1
DAK 1 0 1
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Table 3. Chi-square analysis of transfusion and laboratory variables 
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IMMUNOHEMATOLOGY, Volume 26, Number 3, 201090
Alloimmunized thalassemic patients were more likely to 
have a positive DAT than nonalloimmunized patients (OR, 
2.2); however, this was not statistically significant (p = 0.11). 
All of the patients with a warm autoantibody had a positive 
DAT (p = 0.03). Blood group B patients were 2.6 times less 
likely to have a positive DAT compared with other blood 
groups (χ2, 3.28; p = 0.07). (Table 5)
Discussion
 The DAT may be used as a sensitive method to detect a 
hemolytic transfusion reaction, hemolytic disease of the fe-
tus and newborn, or early alloimmunization, or to diagnose 
autoimmune hemolytic anemia. In this patient population, 
the high rate of positive DATs could not be explained by 
any of these alloimmune phenomena, because the major-
ity (65.4%) of IgG-reactive DATs had a nonreactive eluate. 
Clinical and laboratory factors were analyzed to see wheth-
er a relationship existed between a positive DAT and age, 
race, transfusion frequency, blood group, hepatitis C, sple-
nectomy status, IgG level, blood group, and alloimmuniza-
tion or autoimmunization status. The following variables 
were significantly associated with a positive DAT: older 
age, Caucasian race, elevated gamma globulin levels, pres-
ence of anti-HCV antibody, splenectomy, and presence of 
a warm autoantibody. Because HCV and a splenectomized 
state are known to cause elevated IgG levels and older pa-
tients were more likely to be HCV positive, a multivariate 
analysis was performed to determine whether age, race, 
HCV, splenectomy, and IgG level were independent risk fac-
tors for a positive DAT. This analysis revealed that the only 
true independent risk factors were an increase in IgG lev-
els and HCV positivity. The association between increased 
age and positive DAT may be attributable to the increased 
likelihood of HCV positivity in these patients as many were 
multiply transfused before the institution of HCV serologic 
testing of blood donors in 1992. The possible association 
with a positive DAT and Caucasian race appears to be relat-
ed to the fact that the non-Caucasian patients were younger 
(median, 16 years of age versus median, 35 years of age) 
and therefore less likely to be HCV positive. Patients with 
blood group B were less likely to have a positive DAT, and 
patients alloimmunized to RBC antigens were more likely 
to have a positive DAT, but these associations were not sta-
tistically significant.
 Laboratory and clinical data were reviewed to determine 
whether there was any clinical significance of a positive DAT 
with a nonreactive eluate. However, transfusion increments 
were normal, and no evidence of hemolysis or transfusion 
reaction was noted in the DAT-positive patients. Only 2 of 
288 positive DATs during the period studied revealed a new 
alloantibody that was not detected in serum.
 It was noted during our study that the rate of alloimmu-
nization in our β-thalassemia patients (32.5%) was at the 
higher end of the spectrum of those previously reported; 
alloimmunization rates described previously range from 3 
to 37 percent.7–10 This variability can be explained by dif-
ferences in RBC antigen matching methods across previous 
studies. Some institutions match for DCcEeK in their sickle 
cell and thalassemia patients. We currently match only for 
ABO and D. Furthermore, we use a more sensitive method 
of antibody detection than that used in many of the older 
studies (gel versus tube methodology).7–10
 It is known that β-thalassemia patients have high lev-
els of serum IgG, even in patients not yet transfused. Sple-
nectomized thalassemia patients have even higher levels of 
IgG.5 Multiple studies in general patient populations have 
shown that increased serum IgG levels are associated with a 
positive DAT and a nonreactive eluate, as seen in our study 
in thalassemic patients.1,2,11,12 In a very small study, Gar-
ratty6 previously reported increased IgG bound to RBCs in 
thalassemic patients. He found increased numbers of IgG 
molecules bound to RBCs by the complement fixation an-
tiglobulin consumption assay in 6 of 9 patients with thalas-
semia syndromes. There is debate, however, as to whether this 
bound antibody is caused by cytophilic IgG or autoantibody.
 The aging of a circulating RBC is associated with a 20 
to 30 percent reduction in sialic acid within the RBC mem-
brane. It has been suggested that the cells of the reticuloen-
dothelial system recognize a determinant on the aging RBCs 
produced after sialic acid removal.6 Evidence also suggests 
that RBC-bound IgG may be responsible for the removal of 
senescent human RBCs. Thus, it has been theorized that loss 
of sialic acid creates a “senescent cell antigen” that binds to 
an autologous IgG antibody specific for that antigen.13 Once 
IgG is bound, the senescent cells are quickly phagocytosed 
by macrophages and removed from circulation.6 The site 
and molecular changes of the senescent antigen have not 
been definitively described.
 Kahane et al.14 found that sialic acid residues on the RBC 
surface RBC of thalassemic RBCs are distributed in an uneven 
manner and are less abundant than those present on normal 
RBC surfaces. It follows that thalassemic RBCs would also have 
an exposure similar to that of the senescent cell antigen and IgG 
could bind to these sites on thalassemic RBCs. In this case the 
antigen would not be caused by senescence, but perhaps be at-
tributable to defective membrane biogenesis or an enhanced 
rate of removal of sialic acid from the thalassemic membrane. An 
autologous antibody may also bind to these sialic acid–depleted 
membranes, signaling to macrophages that such cells should be 
removed from circulation.15 Similarly, low levels of sialic acid in 
RBC membranes have been reported in patients with sickle cell 
anemia.
 Therefore, it is not surprising that we would find such 
a high prevalence of positive DATs with IgG bound and 
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Table 5. Frequency of ABO groups
DAT group A B* AB O
DAT+ 13 7 2 20
DAT– 9 13 1 15
*χ2 = 3.28; p = 0.07.
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nonreactive eluates in this patient population. The ques-
tion that still remains to be answered is the following: if 
all thalassemic RBCs have reduced sialic acid, why do only 
half of our patients with thalassemia have antibody bound 
to their RBCs? The answer to this question may be found 
in the complexity and diversity of the immune system, as 
well as in the clinical and molecular heterogeneity of thal-
assemia. Epigenetic and genetic factors most likely play a 
role in RBC autoimmunization as they do in the regulation 
of RBC alloimmunization. In addition, the frequency with 
which a patient is transfused and the percentage of autolo-
gous RBCs in a patient’s circulation may affect the occur-
rence of a positive DAT. From data gathered in our study, 
however, this last explanation cannot be the sole reason for 
a positive DAT, as the most frequently transfused patients 
were not more likely to have a positive DAT. It does seem 
that either underlying genetic or epigenetic factors have a 
role in the positive DAT autoimmunization phenomena, as 
the occurrence of a positive DAT differed by race and blood 
group.
 It was not unexpected that elevated levels of IgG in thal-
assemia patients would lead to a positive DAT with a non-
specific eluate. However, it was unexpected that patients 
with hepatitis C would have a positive DAT independent 
of their IgG level. This is most likely related to the auto- 
reactive manifestations associated with HCV infection, such 
as autoantibody production, cryoglobulinemia, and thy-
roid disorders. It may be that autoantibodies or antibodies 
cross-reactive with common RBC antigens are transiently 
present and account for the temporary positive DATs in 
these patients. This requires further investigation.
 Performing routine DATs on pretransfusion specimens 
in thalassemic patients has limited clinical utility. The posi-
tive DAT reflects the pathophysiology of this disease in the 
majority of patients and does not predict decreased RBC 
survival. Although eliminating this testing may miss a new, 
low-titer alloantibody, this occurrence would be very rare, 
and the antibody probably clinically insignificant, as cur-
rent antibody screening methods are quite sensitive. Elimi-
nating the pretransfusion DAT in this patient population 
will improve turnaround time and decrease costs for the 
patient and health-care system.
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